救治1例重症原发免疫性血小板减少症患者的病例报道
A Case Report of Treating a Patient with Severe Primary Immune Thrombocytopenia
DOI: 10.12677/acm.2024.1482348, PDF,   
作者: 田 明, 陈 鸣*, 朱可嘉：中国人民解放军95829部队医院肾内科，湖北 武汉；金 磊：中国人民解放军95848部队卫生连，湖北 武汉；李静娴：武汉市武昌区黄鹤楼社区卫生服务中心，湖北 武汉
关键词: 原发免疫性血小板减少症；免疫球蛋白；重组人血小板生成素；海曲泊帕；病例报道；Primary Immune Thrombocytopenia； Immunoglobulin； Recombinant Human Thrombopoietin； Herombopag； Case Report
摘要: 原发免疫性血小板减少症(primary immune thrombocytopenia, ITP)是一种以免疫介导的血小板减少性疾病，该病出血风险性高，尤其是致命性颅内出血，重症患者积极准确诊治可以帮助患者度过危险期。本文旨在报道我科的一名重症ITP患者的救治过程，总结该患者的病历资料，并对ITP的发病机制及治疗方法进行探讨。
Abstract: Primary immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenia disease, which has a high risk of bleeding, especially fatal intracranial hemorrhage. Active and accurate diagnosis and treatment of severe patients can help them overcome the critical period. The purpose of this paper is to report the treatment process of a severe ITP patient in our department, summarize the patient’s medical history, and discuss the pathogenesis and treatment of ITP.
文章引用：田明, 陈鸣, 朱可嘉, 金磊, 李静娴. 救治1例重症原发免疫性血小板减少症患者的病例报道[J]. 临床医学进展, 2024, 14(8): 1262-1267. https://doi.org/10.12677/acm.2024.1482348

参考文献

[1] 王吉耀, 葛均波, 邹和建, 等. 实用内科学[M]. 第16版 下. 北京: 人民卫生出版社, 2022: 1612.
[2] 中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版) [J]. 中华血液学杂志, 2020, 41(8): 617-623.
[3] Lee, J.Y., Lee, J., Lee, H., Kang, B., Kim, J., Kim, S.H., et al. (2017) Epidemiology and Management of Primary Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea. Thrombosis Research, 155, 86-91. [Google Scholar] [CrossRef] [PubMed]
[4] Moulis, G., Palmaro, A., Montastruc, J., Godeau, B., Lapeyre-Mestre, M. and Sailler, L. (2014) Epidemiology of Incident Immune Thrombocytopenia: A Nationwide Population-Based Study in France. Blood, 124, 3308-3315. [Google Scholar] [CrossRef] [PubMed]
[5] Zufferey, A., Kapur, R. and Semple, J. (2017) Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). Journal of Clinical Medicine, 6, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[6] Colunga-Pedraza, P.R., Peña-Lozano, S.P., Sánchez-Rendón, E., De la Garza-Salazar, F., Colunga-Pedraza, J.E., Gómez-De León, A., et al. (2022) Oseltamivir as Rescue Therapy for Persistent, Chronic, or Refractory Immune Thrombocytopenia: A Case Series and Review of the Literature. Journal of Thrombosis and Thrombolysis, 54, 360-366. [Google Scholar] [CrossRef] [PubMed]
[7] 胡星月, 赵彤, 张思源, 等. 联合用药治疗成人原发免疫性血小板减少症[J]. 中国医药科学, 2023, 13(14): 45-48, 85.
[8] Mei, H., Liu, X., Li, Y., Zhou, H., Feng, Y., Gao, G., et al. (2021) A Multicenter, Randomized Phase III Trial of Hetrombopag: A Novel Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia. Journal of Hematology & Oncology, 14, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[9] Molineux, G. and Newland, A. (2010) Development of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia: From Bench to Bedside. British Journal of Haematology, 150, 9-20. [Google Scholar] [CrossRef] [PubMed]
[10] 唐广, 张晓南, 武永强, 等. 重组人血小板生成素联合糖皮质激素治疗重症新诊断原发免疫性血小板减少症的效果观察[J]. 中国实用医刊, 2023, 50(16): 105-108.
[11] 郭冠一. 利妥昔单抗联合地塞米松治疗原发免疫性血小板减少症有效性及安全性的系统评价及Meta分析[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2022.
[12] Chugh, S., Darvish-Kazem, S., Lim, W., Crowther, M.A., Ghanima, W., Wang, G., et al. (2015) Rituximab Plus Standard of Care for Treatment of Primary Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. The Lancet Haematology, 2, e75-e81. [Google Scholar] [CrossRef] [PubMed]
[13] 胡倩倩. 基于数据挖掘探讨中医药治疗成人原发免疫性血小板减少症的用药规律[D]: [硕士学位论文]. 武汉: 湖北中医药大学, 2023.
[14] Chaturvedi, S., Arnold, D.M. and McCrae, K.R. (2018) Splenectomy for Immune Thrombocytopenia: Down but Not out. Blood, 131, 1172-1182. [Google Scholar] [CrossRef] [PubMed]
[15] 郭红霞, 赵雪芸. 成人原发免疫性血小板减少症慢性化的危险因素分析[J]. 中国医药科学, 2023, 13(24): 131-134.

为你推荐